Kronos Bio Inc KRON:NASDAQ

RT Quote | NASDAQ | USD
Last | 07/01/22 EDT
3.86quote price arrow up+0.22 (+6.04%)
Volume
165,941
52 week range
2.96 - 25.01
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.86
  • 52 Week High25.01
  • 52 Week High Date09/10/21
  • 52 Week Low2.96
  • 52 Week Low Date06/13/22

Key Stats

  • Market Cap218.98M
  • Shares Out56.73M
  • 10 Day Average Volume0.71M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-71.6

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.86
  • 52 Week High25.01
  • 52 Week High Date09/10/21
  • 52 Week Low2.96
  • 52 Week Low Date06/13/22
  • Market Cap218.98M
  • Shares Out56.73M
  • 10 Day Average Volume0.71M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-71.6

RATIOS/PROFITABILITY

  • EPS (TTM)-2.92
  • P/E (TTM)-1.32
  • Fwd P/E (NTM)-1.28
  • EBITDA (TTM)-159.401M
  • ROE (TTM)-42.31%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kronos Bio Inc

There is no recent news for this security.

Profile

MORE
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is...
Arie Belldegrun M.D.
Non-Executive Independent Chairman of the Board
Norbert Bischofberger Ph.D.
President, Chief Executive Officer, Director
Barbara Kosacz J.D.
Chief Operating Officer, General Counsel
Yasir Alwakeel M.D.
Chief Financial Officer, Head of Corporate Development
Jorge Dimartino M.D., Ph.D.
Executive Vice President - Clinical Development, Chief Medical Officer
Address
1300 S. El Camino Real, Suite 400
San Mateo, CA
94402
United States

Top Peers

SYMBOLLASTCHG%CHG
VKTX
Viking Therapeutics Inc
2.82-0.07-2.42%
ALDX
Aldeyra Therapeutics Inc
3.80-0.19-4.76%
PRVB
Provention Bio Inc
3.43-0.57-14.25%
TNYA
Tenaya Therapeutics Inc
5.45-0.18-3.20%
VSTM
Verastem Inc
1.13-0.03-2.59%